Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors

10 Aug 2020

Abstract excerpt

BACKGROUND: There are ongoing clinical trials exploring the efficacy of dopamine receptor D2 (DRD2) inhibition against glioblastomas, the most common primary brain tumor. Here we examine potential molecular determinants of this efficacy. METHODS: The Cancer Genome Atlas glioblastoma database and other published mRNA profiles were used to analyze the DRD2 and epidermal growth factor receptor (EGFR) expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Stress, Anesthesia, and Immune Response
Share to Glioma Diagnosis and Treatment
Share to Neurotransmitter Receptor Influence on Behavior

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32830856
DOI: 10.1093/neuonc/noaa188

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitorsPMID 32830856Read ↗

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastomaSemantic proximity Read ↗

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 AntagonismSemantic proximity Read ↗

Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5Semantic proximity Read ↗

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.Semantic proximity Read ↗

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastomaSemantic proximity Read ↗

Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in GlioblastomaSemantic proximity Read ↗

The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells.Semantic proximity Read ↗

Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cellsSemantic proximity Read ↗

Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications.Semantic proximity Read ↗

Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.Semantic proximity Read ↗

DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLCSemantic proximity Read ↗

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.